UPDATE 1-Synovis posts Q3 net loss on charges, shares fall

* Q3 loss/shr $0.42 vs yr-ago EPS $0.14

* Records charges of $7.1 mln

* Shares fall 15 percent

Sept 2 (Reuters) - Medical device maker Synovis Life Technologies Inc SYNO.O posted a third-quarter net loss, primarily due to charges related to the impairment of auction rate securities and the purchase of certain assets, sending its shares down as much as 15 percent.

For the third quarter ended July 31, the company posted a net loss of $4.9 million, or 42 cents a share, compared with a profit of $1.8 million, or 14 cents a share, a year earlier.

For the latest quarter, Synovis recorded charges totaling $7.1 million, or 61 cents per share, related to auction rate securities, the purchase of the assets of Pegasus Biologics and write-offs of intangibles related to a lower priority product.

Excluding the special charges, the company reported an adjusted profit of 19 cents per share.

Revenue rose 12 percent to $15.0 million.

Shares of the company were trading down 14 percent at $12.93 in late morning trade on Nasdaq. They touched a low of $12.82 earlier in the session.

For the alerts, please double-click [ID:nWNAB5993] (Reporting by Shailesh Kuber in Bangalore; Editing by Anne Pallivathuckal)